Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating myelofibrosis

a technology of myelofibrosis and compositions, applied in the direction of drug compositions, biocides, extracellular fluid disorders, etc., can solve the problems of insufficient mf management options, ineffective current treatment options, and high transplant-related morbidity and mortality,

Inactive Publication Date: 2013-09-26
TARGEGEN
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The described composition and method provide effective treatment options for myelofibrosis, including reducing spleen size, improving constitutional symptoms, decreasing JAK2V617F allele burden, and enhancing bone marrow cellularity, with manageable side effects and the ability to monitor and adjust treatment based on enzyme and hematologic parameters.

Problems solved by technology

The currently available treatments are not effective in reversing the process of MF, be it primary or secondary disease.
However, most patients are not suitable bone marrow transplant candidates because of the older median age at diagnosis, in which transplant-related morbidity and mortality tends to be high.
Thus management options of MF are currently inadequate to meet the needs of all patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating myelofibrosis
  • Compositions and methods for treating myelofibrosis
  • Compositions and methods for treating myelofibrosis

Examples

Experimental program
Comparison scheme
Effect test

example 1

Evaluation of TG101348 in Myelofibrosis

[0083]As used herein, “TG101348” refers to N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide dihydrochloride monohydrate. The subjects in this study were administered with capsule form of TG101348 as described in Example 5. TG101348 was evaluated in a Phase I study for the treatment of myelofibrosis. This study was ongoing at the time the data were collected.

[0084]Background:

[0085]TG101348 is a potent, orally bioavailable, JAK2-selective small molecule inhibitor, that was evaluated in a Phase I study for the treatment of myelofibrosis. The dose-limiting toxicity was asymptomatic grade 3 or 4 amylasemia / lipasemia that was reversible, and the maximum tolerated dose (“MTD”) was 680 mg. The most frequent non-hematological toxicities were mild nausea, vomiting, and / or diarrhea that were easily controlled or resolved spontaneously. Grade 3 / 4 neutropenia and thrombocytopenia were observed in ...

example 2

Evaluation of TG101348 in Myelofibrosis

[0094]The subjects in this study were administered with capsule form of TG101348. TG101348 was evaluated in a Phase I study for the treatment of myelofibrosis. This study is also described in Example 1. This example describes data available at the time of data collection.

[0095]This study was an open-label, multicenter, and dose-escalation study with expanded cohort dose confirmation at MTD. The primary objective of this study was to determine safety / tolerability, DLT, MTD, and pharmacokinetics of TG101348 in subjects with MF. The secondary objective of this study was to evaluate preliminary clinical and pharmacodynamic activity.

[0096]The key eligibility criteria for subjects included: Myelofibrosis (PMF or post-PV / ET MF); High-risk or intermediate-risk with symptomatic splenomegaly / unresponsive to available therapy; ECOG performance status=2; ANC=1×109 / L; Platelet count=50×109 / L; Serum creatinine=2 mg / dL; Total bilirubin=2 mg / dL; AST / ALT=3× upp...

example 3

Evaluation of TG101348 in Myelofibrosis

[0108]The subjects in this study were administered with capsule form of TG101348.

[0109]Study Design:

[0110]The study constituted a Phase 1, dose-escalation trial (MF-TG101348-001). This study is also described in Examples 1 and 2. Study eligible patients were =18 years of age with high- or intermediate-risk primary myelofibrosis (PMF), post-PV MF, or post-ET MF (Tefferi A et al., Leukemia 22:14-22, 2008). Additional eligibility criteria and participating centers are listed in Table 6. All patients provided written informed consent. The primary endpoints were determination of safety and tolerability, dose-limiting toxicity (“DLT”), maximum tolerated dose (“MTD”) and pharmacokinetic (“PK”) behavior of TG101348. The secondary endpoint was assessment of therapeutic activity.

TABLE 6Detailed enrollment criteria for MF-TG101348-001Inclusion CriteriaExclusion Criteria1. Diagnosis of MF (PMF, post-PV MF, or post-1. Any chemotherapy, immunomodulatory drug...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the priority benefit of U.S. provisional application Ser. No. 61 / 410,924, filed Nov. 7, 2010, which is incorporated herein by reference in its entirety.TECHNICAL FIELD[0002]Provided herein are compositions and methods for treating myelofibrosis. The compositions and methods provided herein relate to treatment of myelofibrosis with compounds that inhibit JAK2 or a pharmaceutically acceptable salt thereof or a hydrate thereof.BACKGROUND[0003]Myelofibrosis (“MF”) is a rare disease mainly affecting people of older age. MF is a BCR-ABL1-negative myeloproliferative neoplasm (“MPN”) that presents de novo (primary) or may be preceded by polycythemia vera (“PV”) or essential thrombocythemia (“ET”). Clinical features include progressive anemia, marked splenomegaly, constitutional symptoms (e.g. fatigue, night sweats, bone pain, pruritus, and cough) and weight loss (Tefferi A, N Engl J Med 342:1255-1265, 2000). Median surviva...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/506
CPCA61K9/48A61K9/00A61K31/506A61K9/4866A61P19/08A61P35/00A61P7/00A61K9/4858A61K9/0053A61K2121/00
Inventor JAYAN, ARVINDCACACE, JANICETEFFERI, AYALEW
Owner TARGEGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com